세계의 약물유전체학 기술 시장 리포트 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

The global demand for Pharmacogenomics Technology Market is presumed to reach the market size of nearly USD 15.59 BN by 2030 from USD 7.6 BN in 2022 with a CAGR of 9.4% under the study period 2023 - 2030.

Pharmacogenomics technology, often abbreviated as PGx, is an interdisciplinary field that combines the study of drugs, i.e., pharmacology, and the study of genes and their functions, i.e., genomics, to understand how an individual's genetic makeup influences their response to medications. This field aims to tailor drug therapies to an individual's genetic profile, ultimately leading to more effective and safer drug treatments.

MARKET DYNAMICS:

The Pharmacogenomics technology market is experiencing substantial growth driven by a convergence of factors emphasizing the pivotal role of genetics in healthcare and the potential for more effective and personalized treatments. Pharmacogenomics, which tailors drug therapies to an individual's genetic profile, is at the forefront of this transformation in medicine. Advancements in genomic research and the identification of genetic markers associated with drug responses are expanding the capabilities of pharmacogenomics technology. As healthcare providers and pharmaceutical companies increasingly prioritize drug safety and efficacy, pharmacogenomics offers a valuable solution by identifying patients at risk of adverse reactions and optimizing drug selection and dosing. The rise of personalized medicine, particularly in oncology, is a significant driver, enabling tailored treatment plans based on a patient's genetic makeup. Government initiatives, precision medicine programs, and patient advocacy are further promoting the integration of pharmacogenomics into clinical practice. Ethical considerations and responsible genetic data are used to highlight the need for pharmacogenomics technology to provide safer and more effective healthcare. The Pharmaceutical industry's investment in research and development in this field and the increasing accessibility of genetic testing technology contribute to the market's rapid expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pharmacogenomics technology. The growth and trends of pharmacogenomics technology industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pharmacogenomics technology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Area

• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

By Technology

• PCR
• In-Situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pharmacogenomics Technology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacogenomics Technology market include QIAGEN, GE HealthCare, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PHARMACOGENOMICS TECHNOLOGY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Area
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY THERAPEUTIC AREA

• 5.1 Overview by Therapeutic Area
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Therapeutic Area
• 5.4 Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Historic and Forecast Sales by Regions
• 5.5 Neurological Disorders Historic and Forecast Sales by Regions
• 5.6 Cardiovascular Disease Historic and Forecast Sales by Regions
• 5.7 Immunological Disorders Historic and Forecast Sales by Regions
• 5.8 Infectious Diseases Historic and Forecast Sales by Regions
• 5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY TECHNOLOGY

• 6.1 Overview by Technology
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Technology
• 6.4 PCR Historic and Forecast Sales by Regions
• 6.5 In-Situ Hybridization Historic and Forecast Sales by Regions
• 6.6 Immunohistochemistry Historic and Forecast Sales by Regions
• 6.7 Sequencing Historic and Forecast Sales by Regions
• 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PHARMACOGENOMICS TECHNOLOGY COMPANIES

• 8.1. Pharmacogenomics Technology Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF PHARMACOGENOMICS TECHNOLOGY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. QIAGEN
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. GE HealthCare
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Agilent Technologies Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. F. Hoffmann-La Roche Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. FOUNDATION MEDICINE INC.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Thermo Fisher Scientific Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Leica Biosystems Nussloch GmBH
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies